Abstract:Pemphigoid diseases (PD) are autoimmune skin blistering diseases characterized by autoantibodies directed against proteins of the cutaneous basement membrane zone (BMZ). One of the major antigens is type XVII collagen (BP180), a transmembrane glycoprotein, which is targeted in four PDs: bullous pemphigoid, mucous membrane pemphigoid, linear IgA dermatosis, and pemphigoid gestationis. To date, different epitopes on BP180 have been described to be recognized by PD disease patients’ autoantibodies. Different BP180 epitopes were associated with distinct clinical phenotypes while the underlying mechanisms are not yet fully understood. So far, the main effects of anti-BP180 reactivity are mediated by Fcγ-receptors on immune cells. More precisely, the autoantibody–antigen interaction leads to activation of complement at the BMZ and infiltration of immune cells into the upper dermis and, by the release of specific enzymes and reactive oxygen species, to the degradation of BP180 and other BMZ components, finally manifesting as blisters and erosions. On the other hand, inflammatory responses independent of Fcγ-receptors have also been reported, including the release of proinflammatory cytokines and internalization and depletion of BP180. Autoantibodies against BP180 can also be found in patients with neurological diseases. The assumption that the clinical expression of PD depends on epitope specificity in addition to target antigens, autoantibody isotypes, and antibody glycosylation is supported by the observation that epitopes of PD patients differ from those of PD patients. The aim of the present review is to describe the fine specificities of anti-BP180 autoantibodies in different PDs and highlight the associated clinical differences. Furthermore, the direct effects after binding of the autoantibodies to their target are summarized.

[The use of chromosome variants in clinical cytogenetics (author's transl)].

An efficient method for high-purity anthocyanin isomers isolation from wild blueberries and their radical scavenging activity.

[New aspects on the pathogenesis of bullous pemphigoid].

Case Report: The many faces of bullous pemphigoid

Clinical and immunoserological characteristics of anti‐p200 pemphigoid: Comparisons of patients with epitope spreading and non‐epitope spreading

Pemphigoid nodularis: two case studies and analysis of autoantibodies before and after the development of generalized blistering

Pemphigoid nodularis associated with autoantibodies to the NC16A domain of BP180 and a hyperproliferative integrin profile

Bullous pemphigoid and related subepidermal autoimmune blistering diseases

To Cut is to Cure: The Surgeon's Role in Improving Value

[Bullous pemphigoid: diagnostics and new therapeutic strategies]

Intermolecular Foerster's energy transfer in labeled poly[N-(2-hydroxypropyl)methacrylamide]

A target-controlled infusion regimen for reducing remifentanil-induced coughs

Type XVII collagen: Relevance of distinct epitopes, complement-independent effects, and association with neurological disorders in pemphigoid disorders

Case report: Bullous pemphigoid arising in a patient with scleroderma and multiple sclerosis

A 0.9-V 12-mW 5-MSPS algorithmic ADC with 77-dB SFDR

Diagnosis of infratemporal fossa tumors.

Beyond The Skin: B Cells in Pemphigus Vulgaris, Tolerance and Treatment

Prevalence and genotypes of Giardia duodenalis in 1-2 year old dairy cattle.

[Free radicals formed during UV-irradiation of biological membrane lipids].

When Bullous Pemphigoid Is Not Bullous Pemphigoid: The Importance of Going Beyond Direct Immunofluorescence

Hemidesmosomal Reactivity and Treatment Recommendations in Immune Checkpoint Inhibitor-Induced Bullous Pemphigoid-A Retrospective, Monocentric Study